Minerva Neurosciences Analyst Ratings
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $7
Hold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraints
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Citius Pharmaceuticals (CTXR) and Amylyx Pharmaceuticals Inc (AMLX)
Hold Rating on Minerva Neurosciences: A Deep Dive Into Operational Factors, Financial Performance, and Valuation
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Entrada Therapeutics Inc (TRDA) and Minerva Neurosciences (NERV)
Minerva Neurosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX), Cara Therapeutics (CARA) and Minerva Neurosciences (NERV)
HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $8 Price Target
Minerva Neurosciences (NERV) Receives a Hold From H.C. Wainwright
Analysts' Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Minerva Neurosciences (NERV) and Tenaya Therapeutics (TNYA)
HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $8 Price Target
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV) and Evolus (EOLS)
Minerva Neurosciences Analyst Ratings
Minerva Neurosciences (NERV) Receives a Buy From BTIG
Analysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC) and Minerva Neurosciences (NERV)
Analysts Are Bullish on Top Healthcare Stocks: Minerva Neurosciences (NERV), Exagen (XGN)
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV) and Athira Pharma (ATHA)
JMP Securities Downgrades Minerva Neurosciences to Market Perform From Outperform, Removes $21 Price Target
Minerva Neurosciences (NERV) Was Downgraded to a Hold Rating at JMP Securities
No Data